Company / EPS (Diluted)
Nurix Therapeutics, Inc. EPS (Diluted) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.65
FY2025
5-year range
-$6.59 / -$2.65
FY2021-FY2025
Trend
+28.6%
vs FY2024
Sector context
#144 of 204
Health Care
What the data says
At $-2.65, Nurix Therapeutics, Inc.'s eps (diluted) ranks #144 of 204 in the Health Care sector. Improved from $-3.71 to $-2.65 over the past 2 years.
Based on SEC 10-K filings.
-2.65 in FY2025.
Improved from $-3.71 to $-2.65 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#144 of 204 in Health CareTop 71% of 204This company -$2.65 Sector average -$0.98
▼
-170.5% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 28.6% year-over-year.
- Ranks #144 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.65 | +28.6% |
| FY2024 | -$3.71 | +0.0% |
| FY2023 | -$3.71 | -35.9% |
| FY2022 | -$2.73 | +58.6% |
| FY2021 | -$6.59 | +0.0% |
| FY2020 | -$6.59 | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026